Navigation Links
Scientists from USC and NYU design a molecule that blocks cancer growth in mice

A team of researchers from USC and NYU has developed and patented a small molecule that interferes with cancer progression with minimal side effects.

The molecule prevents two critical proteins from interacting by mimicking the surface topography of one protein like wearing a mask which tricks the other protein into binding with it. This stops a so-called "transcription factor" that controls the transcription of genetic information. That transcription factor is what would have created an aberrant gene expression, contributing to the cancer growth.

Because of the molecule's precision in targeting the protein interaction, the treatment does not appear to produce any side effects when tested animal tumor models.

"This complex represents one of the key focal points in the tumor-promotion," said Bogdan Olenyuk, assistant professor of pharmacology and pharmaceutical sciences at the USC School of Pharmacy, and one of two corresponding authors on a paper about the work. "However, targeting it for therapeutic intervention was a major challenge, since transcription factors do not possess the necessary topographical structures to make them good targets for mimicking drugs.

Instead, the team focused on blocking one of the transcription factor's binding partners a large protein with complex topography that makes it an easier, more "druggable" target.

Teams of researchers from USC and NYU collaborated on the study. Olenyuk led the USC group, which included graduate students Ivan Grishagin and researcher Hanah Mesallati. Paramjit Arora, professor of chemistry at NYU and co-corresponding author on the paper, lead the NYU group, which included graduate student Brooke Bullock Lao and Thomas Brewer.

Their study appears this week in the Proceedings of the National Academy of Sciences (PNAS). The researchers have filed patent applications for the new design, which has already attracted the interest of several pharmaceutical companies.

Targeting the protein-protein interactions has been a longstanding goal of researchers in the field of cancer biology, and became the focus of Olenyuk's research since 2008.

"After completing my postdoctoral project in cancer gene regulation with my mentor Peter Dervan at Caltech and our collaborator Bill Kaelin at Harvard Medical School, I decided to make a major focus of my research on an interdisciplinary problem of targeting oncogenic transcription factors with designed drug-like molecules," he said.

The researchers used Rosetta Software, a design software for molecular structures, to guide their design. They then designed a strategy to graft the specially textured surface onto a stable scaffold.

So far, the molecules have only been tested animal models, but the researchers plan to take the appropriate steps to prepare for the next step to translate these compounds into clinic.


Contact: Robert Perkins
University of Southern California

Related biology news :

1. Scientists discover a natural molecule to treat type 2 diabetes
2. 35 scientists receive early career research program funding
3. Leading cfaed scientists organize international workshop about DNA-based microchips
4. Scientists link honeybees changing roles throughout their lives to brain chemistry
5. Scientists challenge FIFA: Save the 3-banded armadillo
6. Arizona Sate University scientists take steps to unlock the secrets to the fountain of youth
7. Salk scientists reveal circuitry of fundamental motor circuit
8. Scientists propose amphibian protection
9. Scientists figure out staying power of HIV-fighting enzyme
10. Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth
11. Two San Diego scientists elected to the National Academy of Sciences
Post Your Comments:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology: